CompanyARQTNasdaqWestlake Village, CA

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics develops targeted topical therapies for chronic inflammatory skin diseases.

SEC EDGAR ClinicalTrials.gov arcutis.com

424B4Sep 28Latest SEC filing

Sep 9Latest story

September 2026

Arcutis posts results for roflumilast psoriasis extension trial, NCT04286607

Sep 9Trial updateArcutis Biotherapeutics, Inc.roflumilast

August 2026

Arcutis posts pediatric PK results for topical roflumilast in plaque psoriasis

Aug 7Trial updateArcutis Biotherapeutics, Inc.roflumilast

Arcutis posts Q2 2026 profit as ZORYVE sales climb, raises full-year guidance

Aug 5Quarterly updateArcutis Biotherapeutics, Inc.roflumilast

July 2026

Arcutis adds Mirum CEO Chris Peetz to board of directors

Jul 16PeopleArcutis Biotherapeutics, Inc.

Zhongmei Huadong registers Phase 3 roflumilast foam trial for seborrheic dermatitis with Arcutis

Jul 6Trial updateArcutis Biotherapeutics, Inc.roflumilast